A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Publication
, Conference
Tran, B; Kouros-Mehr, H; Fermin, A; Horvath, L; Roncolato, F; Rettig, M; Dorff, T; Tagawa, ST; Subudhi, SK; Antonarakis, ES; Armstrong, AJ ...
Published in: ANNALS OF ONCOLOGY
October 1, 2019
Duke Scholars
Published In
ANNALS OF ONCOLOGY
EISSN
1569-8041
ISSN
0923-7534
Publication Date
October 1, 2019
Volume
30
Start / End Page
353 / 353
Location
Barcelona, SPAIN
Publisher
OXFORD UNIV PRESS
Conference Name
44th Congress of the European-Society-for-Medical-Oncology (ESMO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Tran, B., Kouros-Mehr, H., Fermin, A., Horvath, L., Roncolato, F., Rettig, M., … Scher, H. I. (2019). A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). In ANNALS OF ONCOLOGY (Vol. 30, pp. 353–353). Barcelona, SPAIN: OXFORD UNIV PRESS.
Tran, B., H. Kouros-Mehr, A. Fermin, L. Horvath, F. Roncolato, M. Rettig, T. Dorff, et al. “A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” In ANNALS OF ONCOLOGY, 30:353–353. OXFORD UNIV PRESS, 2019.
Tran B, Kouros-Mehr H, Fermin A, Horvath L, Roncolato F, Rettig M, et al. A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2019. p. 353–353.
Tran, B., et al. “A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” ANNALS OF ONCOLOGY, vol. 30, OXFORD UNIV PRESS, 2019, pp. 353–353.
Tran B, Kouros-Mehr H, Fermin A, Horvath L, Roncolato F, Rettig M, Dorff T, Tagawa ST, Subudhi SK, Antonarakis ES, Armstrong AJ, Petrylak DP, Fizazi K, Salvati ME, Scher HI. A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2019. p. 353–353.
Published In
ANNALS OF ONCOLOGY
EISSN
1569-8041
ISSN
0923-7534
Publication Date
October 1, 2019
Volume
30
Start / End Page
353 / 353
Location
Barcelona, SPAIN
Publisher
OXFORD UNIV PRESS
Conference Name
44th Congress of the European-Society-for-Medical-Oncology (ESMO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis